The articles by Miller1 and Narayanan and Kupperman2 in the July 2006 issue of the Archives discussed some of the ethically complex issues that relate to randomized clinical trials (RCTs) and off-label use of drugs. We would like to heighten the readers' awareness of a few of the ethical concerns that are critical to understanding the depth of the conundrums that face those involved in clinical practice and research.
Packer S, Jampol LM. An Ethical View of the Ranibizumab and Bevacizumab Controversy. Arch Ophthalmol. 2008;126(2):286-287. doi:10.1001/archophthalmol.2007.41